Crinetics Pharmaceuticals (CRNX) Stock Forecast & Price Target

$26.89 -1.98 (-6.86%)

Closing price 04:00 PM Eastern

Extended Trading

$26.88 -0.01 (-0.04%)

As of 05:09 PM Eastern

Crinetics Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 13 Analyst Ratings

Sell
0

Hold
1

Buy
12

Based on 13 Wall Street analysts who have issued ratings for Crinetics Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a hold rating, and 12 have given a buy rating for CRNX.

Consensus Price Target

$73.00
171.48% Upside

According to the 13 analysts' twelve-month price targets for Crinetics Pharmaceuticals, the average price target is $73.00. The highest price target for CRNX is $97.00, while the lowest price target for CRNX is $54.00. The average price target represents a forecasted upside of 171.48% from the current price of $26.89.

Get the Latest News and Ratings for CRNX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Crinetics Pharmaceuticals and its competitors.

CRNX Analyst Ratings Over Time

Type	Current Forecast 4/4/24 to 4/4/25	1 Month Ago 3/5/24 to 3/5/25	3 Months Ago 1/5/24 to 1/4/25	1 Year Ago 4/5/23 to 4/4/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	12 Buy rating(s)	10 Buy rating(s)	11 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$73.00	$72.64	$74.40	$54.17
Forecasted Upside	171.48% Upside	113.95% Upside	39.98% Upside	16.11% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Moderate Buy

Remove Ads

CRNX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CRNX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Crinetics Pharmaceuticals Stock vs. The Competition

Type	Crinetics Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.92	2.81	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	165.55% Upside	20,727.13% Upside	29.65% Upside
News Sentiment Rating	Positive News See Recent CRNX News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/25/2025	Stifel Nicolaus 4 of 5 stars	Alex Thompson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00	+66.94%
2/11/2025	TD Cowen 4 of 5 stars	T. Van. Buren Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
2/4/2025	Wolfe Research 3 of 5 stars	Andy Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
1/22/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Dennis Ding Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$55.00	+41.90%
1/13/2025	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Douglas Tsao Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00 ➝ $81.00	+99.56%
12/16/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Outperform ➝ Market Outperform	$87.00 ➝ $87.00	+62.13%
11/14/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$70.00 ➝ $74.00	+19.35%
9/16/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$90.00 ➝ $90.00	+67.54%
8/9/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$74.00 ➝ $73.00	+51.42%
7/9/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$47.00 ➝ $54.00	+15.16%
Get the Latest News and Ratings for CRNX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
7/2/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$97.00 ➝ $97.00	+110.92%
5/23/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$52.00 ➝ $62.00	+27.78%
5/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$50.00 ➝ $70.00	+41.84%
3/20/2024	Jonestrading Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$52.00 ➝ $56.00	+23.95%
9/11/2023	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$41.00 ➝ $48.00	+200.56%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:10 PM ET.

CRNX Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Crinetics Pharmaceuticals is $73.00, with a high forecast of $97.00 and a low forecast of $54.00.
: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There is currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CRNX shares.
: According to analysts, Crinetics Pharmaceuticals's stock has a predicted upside of 171.48% based on their 12-month stock forecasts.
: Over the previous 90 days, Crinetics Pharmaceuticals's stock had 1 upgrade by analysts.
: Crinetics Pharmaceuticals has been rated by research analysts at HC Wainwright, Jefferies Financial Group, Stifel Nicolaus, TD Cowen, and Wolfe Research in the past 90 days.
: Analysts like Crinetics Pharmaceuticals more than other "medical" companies. The consensus rating score for Crinetics Pharmaceuticals is 2.92 while the average consensus rating score for "medical" companies is 2.81. Learn more on how CRNX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:CRNX) was last updated on 4/4/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Crinetics Pharmaceuticals (CRNX) Stock Forecast & Price Target